# A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive

> **NCT06524518** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 213 (estimated)

## Conditions studied

- DFS

## Interventions

- **DRUG:** Chemotherapy combined with immunization

## Key facts

- **NCT ID:** NCT06524518
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2026-07
- **Final completion:** 2029-12
- **Target enrollment:** 213 (ESTIMATED)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06524518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06524518, "A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06524518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*